| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |